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Mushrooms have been used in folk medicine for thousands of years. In this study, the effect of 𝛽-glucan-rich extract of P. sajor-caju
(GE) on lipid lowering and antioxidant potential was assessed in C57BL/6J mice fed on a high-fat diet. Obesity was induced in
C57BL/6J mice by feeding a high-fat diet. The control groups in this study were ND (for normal diet) and HFD (for high-fat diet).
The treated groups were ND240 (for normal diet) (240mg/kg b.w) andHFD60, HFD120, andHFD240 (for high-fat diet), where the
mice were administrated with three dosages of GE (60, 120, and 240mg GE/kg b.w). Metformin (2mg/kg b.w) served as positive
control. GE-treated groups showed significantly reduced body weight, serum lipid, and liver enzymes levels. GE also attenuated
protein carbonyl and lipid hydroperoxide levels by increasing the enzymic antioxidants (SOD, CAT, and GPx) activities in the
mice. GE-treated groups induced the expression of hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) while
downregulated the expression of peroxisome proliferator-activated receptor gamma (PPAR-𝛾), sterol regulatory binding protein-1c
(SREBP-1c), and lipoprotein lipase (LPL). Hence, GE prevented weight gain in the mice by inducing lipolysis and may be valuable
in the formulation of adjuvant therapy for obesity.
1. Introduction
Obesity has reached epidemic proportions and is a major
contributor to the global burden of chronic disease and
disability because of its increasing prevalence in all age
groups, sex, and race with the changes of lifestyles and
dietary intake. A recent statistical report by theWorld Health
Organization showed that one out of ten adults were over-
weight; hence, there are more than one billion overweight
adults [1, 2]. Besides that, according to the National Health
and Morbidity Surveys (2011), 15.1% of Malaysians aged 18
and above were obese thus Malaysia has the highest rate
of obesity in south east Asia and the 6th in Asia. Obesity
is a chronic metabolic disorder that results from the dise-
quilibrium between energy intake and energy expenditure.
It is characterized by enlarging fat mass and elevated lipid
concentration in blood. The amount of fat mass is increased
when the number and size of adipocytes are increased by
proliferation and differentiation [3]. The obvious alternatives
for the treatment of obesity are diet, exercise, and surgical
intervention such as bariatric surgery, Roux-en-Y gastric
bypass, gastric banding, and sleeve gastrectomy. However,
it is proven to be successful only in a small minority of
the population [4, 5]. Drugs that are currently available for
the management of obesity, include orlistat (Xenical) which
reduces intestinal fat absorption through inhibition of pan-
creatic lipase and sibutramine (Reductil), and appetite sup-
pressant [2] which was found to cause numerous side-effects
which include valvular heart disease, high blood pressure, dry
mouth, constipation, and headache [6]. Multiple risk factor
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syndrome or metabolic syndrome such as insulin resistance
[7], diabetes mellitus [8], cardiovascular disease, stroke,
hypertension [9], and dyslipidemia [10] is a growing medical
problem in industrialized countries. Obesity is the central
and causal component in this syndrome [11]. Furukawa et al.
[11] reported that in obese individuals, elevated reactive
oxygen species (ROS) upregulates the expression of NADPH
oxidase, establishing a vicious cycle that augments oxida-
tive stress in adipocytes and blood circulation. The ROS
will increase the expression of chemoattractants such as
monochemoattractant proteins-1 (MCP-1), by-products of
lipid oxidation (lipid hydroperoxides and malondialdehyde
(MDA)), and protein oxidation (protein carbonyl) [12, 13]
which are linkedwith systemic inflammationwhich then lead
to the development of metabolic syndrome. However, it is
also well reported that antioxidants can inactivate these ROS
and thus prevent metabolic deregulation includingmetabolic
syndrome [14].
Mushrooms are well known for their medicinal proper-
ties and have been widely used in traditional medicine. The
medicinal effects of mushrooms include antioxidant, antivi-
ral, antibacterial, antifungal, antiparasitic, detoxification,
immunomodulatory, antitumor, radical scavengers, antiin-
flammatory, antihyperlipidemic, or antihypercholesterolem-
ic, hepatoprotective, and antidiabetic [14]. In Malaysia, the
genus Pleurotus (oyster mushroom) which has been shown
to have definite nutritive (high quality proteins, vitamins, and
very little lipids or starch) and medicinal values is widely cul-
tivated. This mushroom is mostly popular in countries such
as India, China, and Japan and is reported to be able to reduce
the cholesterol level in blood [15] and prevent hyperglycemia,
insulin resistance, and inflammation in adipose tissue [16].
Pleurotusmushroom is rich in fiber yet low in calories and fat,
and it has been cited as a potential weight-loss aid.Thedietary
fibers in the mushroom consist of chitin, hemicelluloses,
mannans, and 𝛽-glucans. Beta-glucans are polysaccharides
with glucose residue linked by beta glycosidic bonds. The
fermentability of 𝛽-glucans and their ability to form highly
viscous solutions in the human gutmay constitute the basis of
their antiobesity benefits [17]. Natural products containing𝛽-
glucans have been used for thousands of years, but 𝛽-glucans
were only identified as active components recently.Therefore,
this study was undertaken to investigate the effects of 𝛽-
glucan-rich extract (GE) from P. sajor-caju on prevention of
obesity and oxidative stress in C57BL/6J mice fed on a high-
fat diet.
2. Materials and Methods
2.1. Mushroom Samples. All necessary permits and per-
mission for the collection of materials for the described
field study were obtained, and the party involved is duly
acknowledged. Fresh fruiting bodies of Pleurotus sajor-
caju (10 kg) were grown and collected from Mr. Kuan Kek
How mushroom farm in Semenyih, Selangor Darul Ehsan,
Malaysia. Authentication of P. sajor-caju was carried out
by the Mushroom Research Centre (MRC), University of
Malaya, and a voucher material (KUM 50082) for this study
was deposited at the MRC culture collection.
2.2. Isolation and Purification of GE. The isolation and
purification of GE were carried out based on the method
described by Roy et al. [18]. The 𝛽-glucan level in GE
was estimated using the 𝛽-glucan kit (specific for mush-
room and yeast) purchased from Megazyme International
(Ireland). The enzyme kit contains exo-1,3-𝛽-glucanase, 𝛽-
glucosidase, amyloglucosidase and invertase, glucose deter-
mination reagent (GOPOD-glucose oxidase, peroxidase, and
4-aminoantipyrine), and glucose standard solution. The esti-
mation of total glucan content was done by hydrolysing GE
with 37% hydrochloric acid (v/v) for 45 minutes at 30∘C and
continued for 2 hours at 100∘C. After neutralization with
2M potassium hydroxide, glucose hydrolysis was carried
out using a mixture of exo-𝛽-(1-3)-D-glucanase and 𝛽-
glucosidase in sodium acetate buffer (pH 5.0) for 1 hour at
40∘C. To measure the total glucan content, glucose oxidase-
peroxidase mixture was added to GE and incubated for 20
minutes at 40∘C. The absorbance of the resulting colour
complex was measured using a spectrophotometer (Bio-
Tek Instruments Inc, USA) at 510 nm. The 𝛼-glucan content
was estimated according to the same method as described
above after enzymatic hydrolysis with amyloglucosidase and
invertase.The𝛽-glucan content was calculated by subtracting
the 𝛼-glucan from the total glucan content. Glucan content
was expressed as percentage (w/w) of dry weight (DW).
2.3. Animals and Ethics Statement. This study was conducted
in conformity with the policies and procedures of the Animal
Care andUseGuidelines of Faculty ofMedicine, University of
Malaya, with reference to the 8th edition ofGuide for theCare
and Use of Laboratory Animals by the Institute of Laboratory
Animal Research, National Academy of Science, USA. The
animal ethics approval was obtained from Animal Care and
Use Committee of Faculty of Medicine, University of Malaya
(IACUC, UM) (approval number: ISB/14/07/2010/GK [R]).
Female C57BL/6j mice (7 weeks old) were purchased from
BioLasco Laboratory, Taiwan. The animals were maintained
in stainless steel wiremesh cages in a room kept at 21∘Cwith a
standard condition of 12-hour light/dark cycle (light period:
8:00–20:00 hour) with free access to food and water which
were provided fresh every day.
2.4. Experimental Design. After one week of acclimatisation,
the mice were randomly assigned (based on weight) into
seven groups (𝑛 = 6). Table 1 shows the type of diet and
concentration of GE administered to each group. On caloric
basis, the normal diet contained 5% fat, 69.2% carbohydrate,
and 25.8% protein whereas the high-fat diets (TestDiet, USA)
comprised 45% of fat (46.1% fat from lard, 35.8% carbohy-
drate, and 18.1% protein) and 60% of fat (61.6% fat from lard,
20.3% carbohydrate, and 18.1%protein).GEwas administered
thrice a week via epigastric route using a feeding needle (size
20) to groups ND240, HFD60, HFD120, and HFD240 for 16
weeks. In this study, metformin (2mg/kg b.w) was used as
the positive control (HFDMET) since metformin has been
reported to have comparable effects with orlistat (antiobesity
drug) [19], and it is also widely used to treat type 2 diabetes
which is closely associated with obesity [11]. After 7 weeks
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Table 1: Type of diet and concentration of GE/metformin adminis-
trated to each group.
Type of diet Groups Treatment
Normal diet
ND Normal diet only + saline
ND240 Normal diet + 240mg/kg of bodyweight GE
High-fat diet
HFD High-fat diet only + saline
HFD60 High-fat diet + 60mg/kg of bodyweight of GE
HFD120 High-fat diet + 120mg/kg of bodyweight of GE
HFD240 High-fat diet + 240mg/kg of bodyweight of GE
HFDMET High-fat diet + 2mg/kg of bodyweight of metformin
of feeding with 45% of fat, the animal diet was substituted
with 60% of fat for groups HFD, HFD60, HFD120, HFD240
and HFDMET. The diet for groups ND and ND240 was
not altered throughout the experiment. For the normal diet
group, only 240mg/kg of body weight of GE (highest dose)
was administrated to the mice in order to reduce the usage of
mice.
2.4.1. Sample Collection andAnalyticalMethods. Bodyweight
and food consumption were monitored daily. During the
experimental period, urine was collected from each group
weekly (every Monday morning at 10:00 hour). At the end
of the 16 weeks, the mice were anesthetized with ether after
withholding food for 12 hours and were sacrificed by aortic
exsanguination. Blood samples were collected in a SST glass
serum tube with gold BDHemogard closure (BD Vacutainer,
USA). Serum samples were separated after centrifugation
at 2400×g for 15 minutes. The serum samples from each
mouse (within a group) were pooled together in order to
have sufficient serum for further analysis. The pooled serum
samples were sent to the Clinical Diagnostic Laboratory
Unit, University Malaya Medical Centre, for the serum lipid
and liver analysis. Immediately after blood collection, the
liver and kidney were perfused in-situ with ice-cold saline.
The weight of the liver and kidney of mice from each
group were recorded. Eight mL of ice-cold phosphate buffer
saline (PBS) was added to one gram of liver or kidney.
The samples were then homogenized using a homogenizer
(WiseMixHG-15A,Germany). Adipose tissueswere removed
and stored in RNAlater solution (Applied Biosystems, USA)
and refrigerated at 4∘C overnight. All samples were then
stored at −80∘C until further analysis was carried out.
2.5. Urinary Oxidative Indices Measurement. The protein
carbonyl content (AOPP) was determined as previously
described [20]. Chloramine-T solution of known concen-
trations (0 to 500𝜇M) was used as a standard for the
estimation of AOPP concentration, and the result was
expressed as 𝜇M of chloramine-T. Lipid hydroperoxide
level was determined based on the method described by
Esterbauer and Cheeseman [21] with modifications. 1,1,3,3-
Tetraethoxypropane (TEP) solution of known concentration
(2.5 to 20𝜇M) was used as a standard for quantification, and
the result was expressed as 𝜇M of TEP. The DNA damage
level was quantified using 8-hydroxy-2-deoxy-Guanosine
(8-OHdG) EIA kit (Cayman Chemical, USA). 8-Hydroxy-
2-deoxy-Guanosine hydroxyl EIA standard (10.3 pg/mL to
30 ng/mL) was used for quantification, and the result was
expressed as pg/mL.
2.6. Enzymic Antioxidant Activity Measurement. The kidney
and liver tissue homogenates were used to measure the
activities of superoxide dismutase (SOD [EC-1.15.1.1]), glu-
tathione peroxidase (GPx [EC-1.11.1.9]), and catalase (CAT
[EC-1.11.1.6]). Commercially available kits were used for SOD,
CAT, and GPx assays (Calbiochem, Germany). The protein
content of the homogenates was determined using the Bio-
Rad Protein Assay (Barcelona, Spain) [22] with bovine serum
albumin as a standard. Enzyme activities were expressed in
units per milligram of protein. One unit of SOD activity
was defined as the amount of enzyme that exhibited 50%
dismutation of the superoxide radical. One unit of CAT
activity was defined as the amount of enzyme that caused
the formation of 1.0 nmol formaldehyde per min. The unit of
GPx activity was expressed as nanomoles of NADPH permin
(calculated using an extinction coefficient of 0.00373𝜇M−1).
2.7. Lipid Peroxidation Assay (LPO). The LPO assay was
determined according to the modified method of Kup-
pusamy et al. [23] based on thiobarbituric acid reaction in
which MDA was used as an index of lipid peroxidation.
Trichloroacetic acid (15%) and thiobarbituric acid (1%) were
added to the tissue homogenates in triplicates. The mixtures
were incubated in boiling water bath for 10 minutes and
were centrifuged at 6000×g for 10 minutes to remove the
sediments. The absorbance was read at 532 nm using a
spectrophotometer (Bio-Tek Instrument Inc., USA). 1,1,3,3-
Tetraethoxypropane (TEP) solution of known concentration
(2.5 to 20𝜇M) was used as a standard for quantification, and
the result was expressed as mmol/L of TEP.
2.8. Gene Expression Using Real Time: RT-PCR. The total
RNA was isolated from the adipose tissue using Ambion
RNAqueous-Micro Kit (Applied Biosystems, USA). The
purity of recovered total RNA was estimated by calculating
the ratio of absorbance reading of 260 nm and 280 nm.
The integrity of RNA was estimated using Agilent 2100
Bioanalyzer (Applied Biosystems, USA). Purified RNA with
an 𝐴
260
/𝐴
280
ratio between 1.8–2.0 and RIN values 8–10 was
further used to synthesize complementary DNA (cDNA) by
polymerase chain reaction (PCR) approach. High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, USA)
which contained all reagents needed (RT buffer, dNTP mix,
random primers, Multiscribe reverse transcriptase enzyme,
and nuclease freewater) for reverse transcription (RT) of total
RNA to single-stranded cDNA was used in this study. The
mixture was then loaded into a thermal cycler (Eppendorf,
USA), and PCR was carried out according to optimized
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Table 2: Genes investigated.
Number Gene name and abbreviation Assay ID Accession number
1 Adipose triglycerides lipase (ATGL/Pnpla2) Mm 00503040 m1 NM 025802
2 Hormone sensitive lipase (HSL/Lipe) Mm 00495359 m1 NM 001039507
3 Lipoprotein lipase (LPL) Mm 00434770 m1 NM 008509.2
4 Peroxisome proliferator-activated receptor 𝛾 (PPAR-𝛾) Mm 01184322 m1 NM 011146
5 Sterol regulatory binding protein (SREBP-1c) Mm 00550338 m1 NM 011480.3
General abbreviation of genes selected for this study and corresponding assay ID and accession number was obtained from the Applied Biosystems website and
NCBI database. Assay ID refers to the Applied Biosystems Gene Expression Assays inventoried kits with proprietary primer and TaqMan probe mix. Assay ID
with “Mm” is referred to as “Mus musculus.” All Gene Expression Assay kits indicated are FAM/MGB probed.
thermal cycling conditions provided by the manufacturer.
Table 2 shows the list of genes investigated in this study and
the corresponding accession numbers. Endogenous control
used in this study was eukaryotic 18S rRNA with FAM/MGB
probe.All TaqMan (AppliedBiosystems,USA) probes used in
this investigation were labeled with FAM reporter dye at the
5󸀠 end and a MGB quencher at the 3󸀠 end. The quantification
approach used was the comparative CT method, also known
as 2−ΔΔCt method [24].
2.9. Statistical Analysis. Data are shown as mean ± SD of
triplicate assays. One-way analysis of variance was used to
estimate the significant differences between groups. Statistical
significance was accepted at 𝑃 < 0.05. Duncan’s multiple
range tests (DMRT) was used to determine the significant
differences between groups. Statgraphics Plus software (ver-
sion 3.0, Statistical Graphics Corp., Princeton, NJ, USA)
was used for all statistical analyses. All figures were drawn
usingGraphPad Prism 5 (GraphPad Software Inc., California,
USA).
3. Results and Discussion
3.1. Weight and Estimation of 𝛽-Glucan Concentration in
GE. Fresh P. sajor-caju (5.5 kg) was boiled for 8 hours to
obtain 12.31 g of GE. The concentration of total glucan in
GE was 85.95% (w/w) meanwhile the concentrations of 𝛼-
glucan and 𝛽-glucan were 5.4% (w/w) and 80.55% (w/w)
which corresponded to 0.01% and 1.5% in fresh mushroom,
respectively [17].
3.2. Effects of GE on the Changes in Body Weight and Serum
Lipid Levels. The test compounds (GE/metformin/vehicle)
were only administered thrice a week to the mice in order
to avoid physical stress.Themean food consumption was not
significantly different between high-fat diet-treated mice and
high-fat diet plus GE-treated mice. Figure 1 shows the effects
of GE and metformin on body weight changes in the mice.
The body weight in the ND group gradually increased during
the 16-week period. In contrast, the body weight of mice
in the HFD group showed a rapid increase of body weight.
The descending order of the percentages of weight gain in
each group was HFD > HFD60 > HFD120 > HFDMET >
ND >HFD240 > ND240. The mice in HFD60, HFD120, and
HFD240 groups had 27.55%, 36.69%, and 39.76% lower body
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Figure 1: Effects of GE and metformin on body weight changes
in C57BL/6J mice fed on a high-fat diet or normal diet. The
concentrations of GE were 60, 120, and 240mg/kg/day. Metformin
(2mg/kg/day) was used as positive control. Values expressed are
means ± S.D of (𝑛 = 6 per group) measurements.
weight, respectively, compared to HFD group. HFDMET
group showed 31.90% lower body weight compared to HFD
group; hence, the potential weight lowering effect of GE-
treated groups were comparable to HFDMET group. Obesity
has been associated with increased triglycerides (TG), very
low-density lipoprotein (VLDL), total cholesterol (TC), and
decreased high-density lipoprotein cholesterol (HDL-c) and
thus is also a risk factor of cardiovascular disease [25]. Table 3
shows the serum lipid profile which includes the levels of
TG, TC, HDL-c, low-density lipoprotein cholesterol (LDL-
c), and atherogenic index (AI). In HFD control group, the
TG level was increased by 33.3%, TC increased by 40%,
HDL-c increased by 34.6%, and LDL-c increased by 171.4%
compared to those in the ND group, thus the mice in HFD
were considered to be hyperlipidemic. Meanwhile, mice in
HFD60, HFD120, and HFD240 groups showed considerably
reduced levels of TG, TC, and LDL-c compared to the HFD
group, and this effect was dose dependent.The percentages of
reduction for TG,TC, andLDL-c levels inHFD60were 12.5%,
7.1%, and 60.5%, respectively. The percentages of reduction
for TG, TC, and LDL-c levels in HFD120 were 25%, 10.7%,
and 81.6%, respectively. The percentages of reduction for TG,
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Table 3: Effects of GE and metformin on lipid profile and AI in C57BL/6J mice fed on a high-fat diet or normal diet.
Groups Serum concentration (mmol/L)
TG TC HDL-c LDL-c AI
ND 0.60 ± 0.02ab 2.03 ± 0.5a 1.87 ± 0.05a 0.14 ± 0.0ab 0.07
ND240 0.70 ± 0.02b 1.80 ± 0.4a 1.79 ± 0.01a 0.01 ± 0.0a 0.01
HFD 0.8 ± 0.2bc 2.80 ± 0.3b 2.52 ± 0.3b 0.38 ± 0.1c 0.11
HFD60 0.70 ± 0.1b 2.60 ± 0.2b 2.35 ± 0.2b 0.15 ± 0.0ab 0.11
HFD120 0.60 ± 0.1ab 2.50 ± 0.2ab 2.41 ± 0.3b 0.07 ± 0.0a 0.07
HFD240 0.60 ± 0.4ab 2.10 ± 0.1a 2.35 ± 0.2b 0.02 ± 0.0a 0.02
HFDMET 0.50 ± 0.0a 2.60 ± 0.3b 2.55 ± 0.3b 0.18 ± 0.0ab 0.02
Values expressed are means ± S.D of (𝑛 = 6 per group) measurements. For same assay with various treatment groups, superscripts in the different bar with
different alphabets (a–c) were significantly different (𝑃 < 0.05). Superscripts with same alphabets were not significantly different between the treated groups
(𝑃 > 0.05). TG is triglycerides; TC is total cholesterol; HDL-c is high-density lipoprotein cholesterol; LDL-c is low-density lipoprotein cholesterol; AI is
atherogenic index.
TC, and LDL-c levels in HFD240 were 25%, 25%, and 94.7%,
respectively. However, there were no significant differences
(𝑃 > 0.05) in the HDL-c level between the treated groups
and control group. The HFDMET group showed decreased
levels of TG (37.5%), TC (7.1%), and LDL-c (52.65%) levels
and increased level of HDL-c (1.2%) compared to the HFD
group. The AI and cardiac risk factor were calculated based
on the measurement obtained from the lipid analysis. The AI
was defined by TC minus HDL-c divided by HDL-c, whilst
the cardiac risk factor was calculated as TC divided by HDL-
c [26]. In this study, the AI risk predictor indices for the
HFD group were increased compared to those in ND and
GE or metformin-treated groups. In accordance to the high
AI risk factor, the cardiac risk factor was also elevated in the
HFD group compared to those in ND and GE or metformin-
treated groups.The reductions in the atherogenic and cardiac
risk indexes in GE-treated groups indicate a decreased risk
of cardiovascular disease [27]. Beta-glucan has been shown
to decrease LDL-c and increase HDL-c to alleviate possibly
dyslipidemia and reduce cardiovascular disease [28]. Oats
were first found to have a cholesterol-lowering effect, and the
active component was identified as beta-glucans [29]. Sim-
ilar serum cholesterol-lowering activity was also observed
in Maitake, Shiitake, and Enokitake mushrooms [30]. The
mechanism for LDL-c lowering by 𝛽-glucans is speculated
to involve bile acid binding. The increased exclusion of bile
acids activates cholesterol 7𝛼-hydroxylase and upregulates
low-density lipoprotein receptor (LDLR) and thus increases
the transport of LDL-c into hepatocytes and the conversion
of cholesterol into bile acids [31].
3.3. Effects of GE on Liver Enzymes. Table 4 shows the effects
of GE and metformin-treated groups on liver enzymes.
Increased liver enzyme concentrations and activity in the
serum are conventionally interpreted as a marker of liver
damage. In this study, the alanine transaminase (ALT),
aspartate transaminase (AST), and alkaline phosphate (ALP)
levels of mice in the HFD group were significantly elevated
compared to the other groups. However, there were no
changes in the glutamyl transferase (GGT) level between
these groups. A recent study demonstrated that obese patients
with increased serum TG level showed raised levels of each
of the four liver enzymes [32]. Weight reductions have been
shown to reduce the liver enzyme levels [33]. The present
study shows that GE confers protection against high-fat diet-
mediated liver damage.
3.4. Effects of GE on the Urinary Oxidative Indices. Oxi-
dation products can be found in the urine and are con-
sidered to reflect local and systemic oxidative stress [34].
Figures 2(a)–2(c) show the AOPP, lipid hydroperoxide, and
8-OHdG levels in each group during the 16 weeks of exper-
iment. The AOPP, lipid hydroperoxides, and 8-OHdG levels
in the ND group gradually increased every week, however,
these oxidative stress indices were significantly elevated in
the HFD group compared with all other groups. The mice
in HFD group were obese, and this may have contributed to
the increased level of oxidative stress indices in the animals
[35]. The AOPP and lipid hydroperoxide levels in GE-treated
groups were lower compared to the HFD group, and this
effect was dose dependent. Similarly, HFDMET also showed
a decrease in AOPP and lipid hydroperoxide levels compared
to the HFD group. The 8-OHdG level was elevated in HFD
group, however, no significant differences were observed
between all the groups tested (𝑃 > 0.05). Studies have
shown that elevated levels of MDA [36], AOPP [37], and 8-
OHdG [38] in obese animals or humans are associated with
several disease conditions including hypertension, diabetes,
cardiovascular diseases, and renal diseases [39].
3.5. Effects of GE on Enzymatic Antioxidant Levels in Liver and
Kidney Homogenates. Fruits, vegetables, spices, herbs, and
mushrooms have been studied for their antioxidant proper-
ties in-vitro extensively [40, 41]. However, the demonstration
of the antioxidant properties of these components in-vivo
is scarce but is gaining importance nowadays. Previously,
antioxidant capacity has been mainly assessed in serum or
plasma after an oral intake of a food infusion. Neverthe-
less, numerous studies have also suggested that oxidative
processes occurring in various tissues and organs in the
human bodymay be crucial in the onset ofmetabolic diseases
[42]. It is reported that, after absorption, the antioxidant
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Figure 2: Effects of GE and metformin on (a) AOPP (b) lipid hydroperoxide, and (c) 8-OHdG levels in urine samples of C57BL/6J mice fed
on a high-fat diet or normal diet. Values expressed are means ± S.D of triplicate measurements (𝑛 = 6 per group). For same assay with various
treatment groups, superscripts in the different bar with different alphabets (a)–(e) were significantly different (𝑃 < 0.05). Superscripts with
same alphabets were not significantly different between the treated groups (𝑃 > 0.05). There was no significant difference observed in the
8-OHdG levels between the groups tested (𝑃 > 0.05).
Table 4: Effects of GE and metformin on liver enzymes in C57BL/6J mice fed on a high-fat diet or normal diet.
Groups Liver enzymes (mmol/L)
Alanine transaminase (ALT) Aspartate transaminase (AST) Alkaline phosphate (ALP) G-glutamyl transferase (GGT)
ND 45 ± 1.2c 182 ± 11.2b 39 ± 1.2a <3
ND240 29 ± 1.1a 148 ± 10.2a 30 ± 1.1a <3
HFD 48 ± 1.4c 210 ± 8.2c 54 ± 0.9c <3
HFD60 46 ± 2.3c 194 ± 12.1b 44 ± 1.4b <3
HFD120 32 ± 2.4b 181 ± 10.1b 38 ± 1.3a <3
HFD240 27 ± 1.4a 176 ± 9.7ab 35 ± 1.3a <3
HFDMET 39 ± 1.33b 189 ± 9.5b 39 ± 1.5a <3
GE concentrations were 60, 120, and 240mg/kg/day.Metformin (MET) is used as positive control. Values expressed aremeans± S.D of triplicatemeasurements.
For same enzyme level with various treatment groups, superscripts in the different bar with different alphabets (a–c) were significantly different (𝑃 < 0.05).
Superscripts with same alphabets were not significantly different between the treated groups (𝑃 > 0.05).
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Table 5: Effects of GE on enzymic antioxidants and MDA levels in the kidney and liver homogenates of C5BL/6J mice fed on a high-fat diet.
Groups
Antioxidant activity (nmol/min/mg protein)
GPx CAT SOD (U/mg protein) LPO (mmol/L)
ND Kidney
Liver
71.08 ± 6.3cd
83.95 ± 10.8b
103.93 ± 4.5d
29.96 ± 3.9c
0.34 ± 0.0d
0.17 ± 0.0b
0.89 ± 0.01e
0.76 ± 0.03b
ND240 KidneyLiver
82.72 ± 6.9d
90.42 ± 11.7b
112.96 ± 4.6e
32.57 ± 6.7d
0.37 ± 0.0d
0.32 ± 0.0d
0.83 ± 0.04d
0.7 ± 0.1ab
HFD KidneyLiver
32.31 ± 3.2a
45.22 ± 5.5a
52.64 ± 1.2a
15.18 ± 8.7a
0.017 ± 0.0a
0.01 ± 0.0a
0.9 ± 0.04e
0.92 ± 0.1c
HFD60 KidneyLiver
32.46 ± 4.9a
68.20 ± 8.3b
79.72 ± 1.3b
22.98 ± 5.7b
0.23 ± 0.0b
0.19 ± 0.0b
0.86 ± 0.02de
0.62 ± 0.1a
HFD120 KidneyLiver
36.16 ± 5.1ab
74.86 ± 8.7b
86.40 ± 11.6bc
24.91 ± 9.7bc
0.27 ± 0.0c
0.23 ± 0.0bc
0.64 ± 0.03b
0.6 ± 0.04a
HFD240 KidneyLiver
44.58 ± 5.3b
61.39 ± 8.9b
84.29 ± 1.5bc
24.30 ± 1.1bc
0.22 ± 0.0b
0.26 ± 0.0c
0.57 ± 0.04a
0.61 ± 0.06a
HFDMET KidneyLiver
66.83 ± 5.5c
119.06 ± 9.3c
89.49 ± 2.7c
25.80 ± 8.5bc
0.20 ± 0.0b
0.19 ± 0.0b
0.74 ± 0.03c
0.64 ± 0.05ab
GE concentrations were 60, 120, and 240mg/kg/day.Metformin (MET) is used as positive control. Values expressed aremeans± S.D of triplicatemeasurements.
For same antioxidant activity with various treatment groups, superscripts in the different bar with different alphabets (a–e) were significantly different
(𝑃 < 0.05). Superscripts with same alphabets were not significantly different between the treated groups (𝑃 > 0.05). GPx is glutathione peroxidase; CAT
is catalase; SOD is superoxide dismutase; LPO is lipid peroxidation.
compounds are transferred through the blood circulation
to various organs [43]. In the present study, the enzymic
antioxidant activities and LPO level were assessed in the
liver and kidney homogenates (Table 5), since these are the
key organs in the mammalian oxidative metabolism. The
natural antioxidant system consists of a series of antioxidant
enzymes and numerous endogenous and dietary antioxi-
dant compounds that react with and inactivate ROS. The
primary antioxidant enzymes include SOD, CAT, and GPx.
Meanwhile, the nonenzymatic antioxidants include vitamin
C, vitamin E, 𝛽-carotene, reduced glutathione (GSH), and
numerous phytochemicals. Cells must maintain their levels
of antioxidants, often defined as their antioxidant potential,
through dietary intake and/or de novo synthesis [44, 45].
Increased levels of ROS in cells and tissues may act as a
signal to enhance the activity and expression of antioxidant
enzymes. A high-fat diet is known to increase the superoxide
anion (O
2
∙–) radicals in the body. Superoxide dismutase con-
verts the O
2
∙– radicals to hydrogen peroxide (H
2
O
2
) which
in turn is converted to water by CAT and GPx. In this study,
theHFD group showed reduced levels of SOD, CAT, andGPx
activities in the kidney and liver homogenates compared to
the ND group. Whereas, GE- and metformin-treated groups
showed increased levels of SOD, GPx, and CAT activities
compared to the control groups (ND and HFD) (Table 4).
Overall, the increased level of antioxidant enzyme activities
in GE- and metformin-treated groups conferred protection
against oxidative damages in the mice, and this speculation is
supported by the attenuated levels of oxidative stress indices
such as AOPP and lipid hydroperoxide levels in the urine as
well as MDA level in the kidney and liver homogenates.
3.6. Effects of GE on the Expression of Differentiation and
Lipolysis Genes in Adipose Tissue. Adipose tissue is a complex
and active secretory organ that both sends and receives
signals that modulate energy expenditure, appetite, insulin
sensitivity, endocrine function, inflammation, and immunity
[46]. Table 6 shows the expression of the selected genes
involved in the differentiation and lipolysis processes in
adipose tissue. The mice fed on a high-fat diet (HFD group)
weighed more and developed substantially more adipose tis-
sue than themice on a normal diet (NDgroup) (Figure 1).The
mice became hyperlipidemic, and this is typically associated
with obesity [47] (Table 3). PPAR-𝛾 and SREBP-1c genes are
the key adipose transcription factors that play important
roles in lipogenesis [48]. These genes act cooperatively and
sequentially to trigger terminal adipocyte differentiation.
The PPAR-𝛾 is expressed selectively in the adipose tissues,
and it promotes the differentiation and proliferation of the
preadipocytes thereby causing an increase in fat mass [49],
while SREBP-1c controls the production of endogenous lig-
ands for PPAR-𝛾 as amechanism for coordinating the actions
of these adipogenic factors [48] and has been implicated as
being a key regulator for fatty acid and triglyceride synthesis
[50]. Meanwhile, LPL is the key enzyme that regulates the
disposal of lipid in the body, and its role is to hydrolyse
triglyceride circulating in the lipoprotein particles in order
to facilitate the uptake fatty acids into the cells [51]. GE-
treated groups had lower expression of PPAR-𝛾, SREBP-1c,
and LPL compared to HFD group. PPAR-𝛾 protein binds
to the promoter regions of adipocyte-expressed LPL gene
[52], and the attenuation of PPAR-𝛾 gene expression in
GE-treated groups could have attributed to the reduced
expression of LPL as well. HSL and ATGL genes are reported
to play an important role in the mobilization of stored
triacylglycerol (TAG) [53].The activation of these genes leads
tomobilization of TAG to form glycerol and fatty acids where
HSL mainly breaks down TAG to form diacylglycerol (DAG)
whilst ATGL breaksdown DAG to form monoacylglycerol
(MAG). Subsequently, MAG is converted to free fatty acids
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Table 6: Effects of GE on the expression of genes in adipose tissue.
Genes investigated ND240 HFD60 HFD120 HFD240 HFDMET
Lipolysis
ATGL 1.34 ± 0.34 1.78 ± 0.67a 6.05 ± 0.42c 5.69 ± 0.34c 3.84 ± 0.98b
HSL 1.98 ± 0.07 2.99 ± 0.17a 6.73 ± 0.42c 6.54 ± 0.32c 4.63 ± 1.16b
Differentiation
LPL −1.05 ± 0.09 −1.93 ± 0.18a −1.12 ± 0.42b −1.17 ± 0.47b −2.22 ± 0.99a
PPAR-𝛾 −1.69 ± 0.19 −2.08 ± 0.69a −1.69 ± 0.48ab −1.02 ± 0.36c −1.07 ± 0.16c
SREBP-1c −1.27 ± 0.65 −1.01 ± 0.16c −3.10 ± 0.44a −2.25 ± 0.30ab −2.30 ± 1.13ab
Results are expressed as fold variation over the appropriate control groups; ND240 indicates fold increase over ND (normal diet control group), and HFD60,
HFD120, HFD240, and HFDMET indicate fold increase over HFD (high-fat diet control group). Fold variations less than one were expressed as negative
numbers (e.g., a fold variation of 0.50 is expressed as−2.00). Values expressed aremeans± S.D of triplicatemeasurements. Statistical significance was calculated
based on the meanΔCT values by DMRT for only mice fed with high-fat diet with or without GE. For same gene with various treatment groups, superscripts in
the different bar with different alphabets (a–c) were significantly different (𝑃 < 0.05). Superscripts with same alphabets were not significantly different between
the treated groups (𝑃 > 0.05).
and glycerol bymonoacylglycerol lipase (MGL) [54].TheGE-
treated groups had significantly upregulated expressions of
HSL and ATGL genes, and the effect was dose dependent.
Therefore, it is feasible to suggest that the reduced weight
gain in the high-fat diet fed mice treated with GE was due
to the reduced adipose differentiation and increased lipolysis
in adipocytes.
4. Conclusion
Previous studies have demonstrated that the lipid lowering
potential of 𝛽-glucans was mainly mediated by either bile
acid binding, delay in the digestion/absorption of fat, or
suppressed appetite. However, in this study, GE prevented
weight gain and hyperlipidemia in C57BL/6J mice fed on a
high-fat diet by inducing lipolysis and inhibiting the differ-
entiation of adipocytes. GE also prevented oxidative stress
caused by obesity by increasing the enzymic antioxidant
activities, hence, GE could serve as a potential candidate for
the management of obesity.
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